Pharmaron, UK Secures MHRA Approval To Manufacture Clinical Drug Product
The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has recently updated Pharmaron’s Hoddesdon license to enable the manufacture of new oral drug products for its partners to support their Phase I/II clinical trials. New drug candidates come with significant technical challenges and Pharmaron’s highly skilled scientists enable the development of enhanced product formulations to provide clients with the best chance of success in their clinical trials.
This achievement builds on Pharmaron’s already strong drug substance (API) development capabilities, which are co-located at the Hoddesdon site. By offering both drug substance and drug product development services from the same location, Pharmaron provides complete end-to-end CMC (Chemistry, Manufacturing and Control) solutions to its partners, enabling them to streamline their novel drug development programs, save time and resources.
“We’re proud to be one of the few service providers to offer API and drug product services from the same site. Enabling the development of more robust product formulations in less time, our clients gain from fewer material movements and audits, and a more seamless scientific approach to both API and drug product.”
Stephen Lewinton, Senior Vice President, UK Operations at Pharmaron
Chemistry, Manufacturing and Control (CMC) Services
Learn more about Pharmaron’s drug substance and drug product development services.
